From insulin to Ozempic, history of Novo Nordisk's CEOs
(Reuters) -Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli Lilly.
The company has had five CEOs in its more than 100 years of history. Jorgensen, who joined in 2017, has had the shortest tenure of all.
Here is a timeline of the company with respect to its CEOs: -
1920s-2000
Danish couple August and Marie Krogh founded Nordsik Insulinlaboratorium in 1923 and commercialized the production of insulin.
The company competed with Novo Terapeutisk Laboratorium, which was founded by brothers Harald and Thorvald Pedersen, until the two merged in 1989.
Knud Hallas Molle was Novo's second CEO from 1961 to 1981. During that time, both companies pursued and developed techniques to produce pharmaceutical products using fermentation.
Mads Ovlisen served as CEO of Novo and Novo Nordisk after its merger from 1981 to 2000.
In 1982, Novo marketed Human Monocomponent Insulin, and in 1987, the first human insulin products were made using genetically engineered yeast cells. Novo launched the NovoPen - the first insulin pen device in 1985.
2000–2017
Lars Rebien Sorensen becomes CEO after serving as the head of Novo's healthcare business. The company's enzymes business was spun off as a separate company, Novozymes A/S in 2000. In 2004, Levemir – a long-acting modern insulin – was launched.
Under Sorensen, the company develops its first GLP-1 drug, a precursor to Ozempic and Wegovy. Liraglutide, a GLP-1 product for treatment of type 2 diabetes, enters phase 3 trials.
Novo Nordisk launches its first GLP-1 product, liraglutide, branded as Victoza in 2009 in Europe and in 2010 in the U.S.
In 2013, Novo Nordisk's semaglutide starts global phase 3 trials. In December 2016, it files semaglutide for regulatory approval in the U.S. and the EU, based on the results from the six trials.
2017-present
In January 2017, Lars Fruergaard Jorgensen became CEO decades after joining the company as a graduate. In December 2017, Ozempic, also known as semaglutide, gets approved in the U.S. for diabetes, the first once-weekly GLP-1 drug.
Wegovy, which uses the same active ingredient as Ozempic, gets approved in the U.S. as a treatment for obesity in June 2021.
In November 2023, U.S. and UK regulators approved Eli Lilly's rival weight-loss treatment Zepbound, after the company's diabetes drug was launched in 2022.
In December 2024, Novo Nordisk's next-generation obesity drug shows lower-than-expected weight loss in a late-stage study, dealing a blow to its ambitions for a successor to Wegovy that is more powerful than rival Lilly's Zepbound.
On May 16, Novo Nordisk says Jorgensen will step down, citing recent market challenges and a slide in the stock since mid-2024.
Jorgensen says in an interview with Danish broadcaster TV2 that he did not see the decision coming and was only informed very recently.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
Weight loss drugs like Ozempic could mess with your birth control — and get you pregnant
A UK watchdog is urging women on GLP-1 weight-loss drugs like Ozempic and Mounjaro to use effective forms of birth control after receiving more than 40 pregnancy-related reports linked to the medications. The warning comes as women flood social media with stories of their so-called 'Ozempic babies' — including surprise pregnancies while on the pill. Trying to shed pounds, not grow a baby bump? Here's what you need to know about GLP-1s, pregnancy and the best contraception options to stay protected. 4 Studies show that at least one in eight US adults have tried GLP-1s. íÅí°íâ¬í¸í½í° íâíµí¼íµíËí°í¾ – What's in your GLP-1? Several GLP-1 drugs dominate the market, including Ozempic and Wegovy. Both contain semaglutide, an active ingredient that mimics a natural hormone in the body that boosts insulin production, slows digestion and curbs appetite. Then there's Saxenda and Victoza, powered by liraglutide, which functions in a similar way. Newer drugs like Mounjaro and Zepbound rely on tirzepatide, a key ingredient that targets a second hormone involved in appetite and blood sugar control. A surprise side effect While gastrointestinal symptoms like nausea, vomiting and diarrhea are common with GLP-1s, the surprise side effect making waves is unexpected pregnancy. The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has received 28 reports related to pregnancy in patients on tirzepatide, and nine each for semaglutide and liraglutide. 4 Women on tirzepatide-based GLP-1s should use barrier contraception. nenetus – In an alert this week, the agency warned that tirzepatide may reduce the effectiveness of oral contraceptives, especially in women with higher body weight. As a result, it recommended using barrier methods like condoms while on drugs like Mounjaro. So far, there's no evidence that GLP-1s affect non-oral birth control like IUDs, implants, patches, or rings, according to the UK's Faculty of Reproductive Healthcare. And yes, the advice applies even to women previously told they were infertile. GLP-1s have been shown to boost fertility by aiding weight loss, reducing inflammation and improving insulin sensitivity — leading some to conceive just months after starting treatment. 4 GLP-1 agonists can increase your fertility, but they can also interfere with pregnancy. Louis-Photo – Can you take GLP-1s while pregnant? Experts say no — at least not yet. There's not enough data to confirm whether GLP-1s are safe during pregnancy. While a some human studies suggests there is no harm in first-trimester use, testing in animals has shown the drugs could increase the risk of miscarriage and birth defects. 4 Scientists are still working to understand whether GLP-1s can negatively impact a developing fetus. Evrymmnt – Another reason to skip GLP-1s while pregnant: they suppress your appetite and can trigger gastrointestinal issues, which may lead to nutrient deficiencies that impact fetal development. The drugs should also be avoided during breastfeeding, since there's not enough research to confirm safety for infants. Trying to conceive? Here's the timeline If you're planning to get pregnant, the MHRA recommended stopping GLP-1s before you start trying to conceive and giving your body time to clear the drugs. For semaglutide users, that means quitting at least two months ahead. If you're on tirzepatide, stop one month before trying. Liraglutide clears the system faster, so you can stop right before you start trying to conceive.
Yahoo
5 hours ago
- Yahoo
Novo Nordisk Stock: Is It Still a Smart Buy?
This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran pharmaceutical company, however. 10 stocks we like better than Novo Nordisk › Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration (FDA) for that indication in mid-2021. Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. It's easy to believe in a company when it's riding high and unopposed. But late in 2023, a new entrant was approved -- mighty American pharmaceutical company Eli Lilly (NYSE: LLY) with its own GLP-1 treatment, Zepbound -- giving Novo Nordisk one of the strongest competitors imaginable. Almost certainly, this won't continue to be a two-car race for long. Other companies, both large and small, in the healthcare field are pushing hard to develop their own obesity drugs, with varying degrees of success. Eli Lilly alone is an intimidating presence. A mainstay on the American pharmaceutical scene, it's grown to a massive size, to the point where it's the most valuable pharmaceutical company in the world by market cap. It can leverage its vast resources to develop and market any kind of medicine it wants, and in the obesity segment, it was already nearly there with Zepbound's FDA-approved-for-diabetes sibling drug, Mounjaro. Since then, it seems Zepbound has carved out a significant market share from Wegovy. Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market. Eli Lilly holds the rest. Like other pharmaceutical industry pundits, Goldman Sachs is predicting that once other obesity drugs are developed successfully and approved, the market will fragment. That's a wholly believable prediction given the zeal and urgency behind many of those efforts. Meanwhile, Novo Nordisk has taken a series of competitive blows that reduced its lead. A shortage of semaglutide -- the main ingredient of Wegovy -- led the FDA to allow compounding pharmacies to make copies of the molecule, essentially producing new competition. Although the shortage is officially over, it showed that Novo Nordisk would be vulnerable if such a situation reoccurred. Another of the numerous fresh setbacks was a head-to-head clinical trial conducted by Eli Lilly, pitting Zepbound against Wegovy. Last December, the results of the study indicated notably more significant weight loss for participants using Wegovy. One internal development also dented investor sentiment on Novo Nordisk, and that was the company's announcement in mid-May that long-serving CEO Lars Fruergaard Jørgensen was stepping down. When enterprises are humming along pleasantly, they rarely experience a top leader's departure. Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy production more under its direct control. That $16.5 billion deal wasn't cheap by any yardstick, but if the new asset is managed well, it should be more than worth the cost ultimately. Novo Nordisk is also keeping up the pace with its own development activities, attempting to succeed with new medications and/or other indications for Wegovy. Its next-generation obesity treatment CagriSema was essentially a flop. However, the company has already had success winning FDA approval for the versatile Wegovy to treat liver disorder metabolic dysfunction-associated steatohepatitis (MASH), and it's developing the drug for a clutch of other ailments. It also has other medications for different disorders in its pipeline. Meanwhile, a score of researchers modeling the future of the obesity market feel that sales of such drugs will blast through the roof. Projections vary, but a typical one is the latest from Morgan Stanley. In May, the veteran investment bank upped its estimate for the market's peak (predicted to occur in 2035) to $150 billion, well up from its previous assumption of $105 billion. The former number is more than 6 times the $24 billion estimated sales of 2024. The very encouraging news for Novo Nordisk bulls like myself is that even if the market gets highly fragmented with numerous competing products and loses significantly more share -- unlikely, given its first-mover prominence and the strength of the Wegovy brand name -- it'll still be a player in a huge market. Yes, competition can be tough. There are a lot of prizes in this game, and more players are entering it. But I think this original player will manage to hold on and thrive, and I continue to consider Novo Nordisk stock a buy. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Novo Nordisk Stock: Is It Still a Smart Buy? was originally published by The Motley Fool
Business of Fashion
7 hours ago
- Business of Fashion
How to Revive a Sleeping Beauty Watch Brand
The dormant Danish watch company Urban Jürgensen was 'resurrected' in Los Angeles on Thursday following a $25 million revamp that its US backers hope will land it a seat at luxury watchmaking's top table inside five years. Acquired by a group of investors led by the American Rosenfield family in 2021 for an undisclosed sum, Urban Jürgensen was originally founded in Copenhagen in 1773 and is revered by watch connoisseurs and collectors. But outside that bubble, the name is largely unknown. According to its co-chief executive Alex Rosenfield, the bubble needs to burst. 'We think that what we're making are watches that people who love and care about watches will love and care about, but the world of people who can enjoy what we're doing is much larger than that,' Rosenfield told the Business of Fashion. 'Too often, watch companies make you feel like if you don't understand the escapement, we don't want to talk to you. Our goal is absolutely the opposite. It has to be beyond the obsessives.' Rosenfield is new to the watch industry. Qualified as a lawyer, he held a number of brand strategy roles in media and fashion before joining Guggenheim Partners, the US investment and financial services firm, which says it has more than $345 billion of assets under management. Rosenfield's father Andy is the firm's president and also an avid watch collector, buying his first Urban Jürgensen watch in the 1990s. Rosenfield Sr, who will continue to advise the company, and his philanthropist wife Betty hosted the relaunch at their $33 million Brentwood mansion. Rosenfield, who is based in Los Angeles, said his family had never intended to buy a watch company but stepped in to acquire Urban Jürgensen after hearing it had fallen on hard times, so they could return it to 'people who will love it and push it forward.' Urban Jürgensen's latest campaign. (Casey Zhang) The Rosenfields, who are reported to own 85 percent of the company, have assembled an impressive cast list. The company's other co-chief executive is Kari Voutilainen, the Finnish watchmaker considered one of the finest talents of his generation. Voutilainen has a minority stake in Urban Jürgensen, as well as his own independent watch company, which makes around 60 pieces a year. Urban Jürgensen's brand identity was developed by Winkreative in London and Chandelier Creative in New York under Rosenfield's direction, with a launch campaign called Time Well Spent shot by Ellen von Unwerth, the award-winning fashion photographer and filmmaker. The company is set to follow the high-value, low-volume model set by many of today's most successful independent watch brands. According to Rosenfield, in its first year, Urban Jürgensen will produce around 70 watches. Three models were introduced at Thursday's launch, with prices ranging from around $115,000 for the UJ-2 to $410,000 for the UJ-1, which will be limited to 75 pieces. Each has a new mechanical movement designed in-house by Voutilainen and hand-finished and assembled at the company's Swiss facility in the city of Biel/Bienne, where watchmaking giant Omega is based. Currently, it employs 20 people, around half of them watchmakers. 'The idea is to bring the glory of the Urban Jürgensen of the 19th century back,' Voutilainen said, referring to a period when the company made watches for the Danish royal court. 'This is just the starting block. Our aim is to make Urban Jürgensen a new reference point in fine watchmaking.' The revival of Urban Jürgensen comes in a busy season of watch brand rebirths. The private equity-backed Swiss company Breitling has in recent years acquired Universal Genève and Gallet, two dormant brands now slated for a comeback next year. Last year, Silvercity Brands, a subsidiary of the Indian conglomerate KDDL, revived the 18th century company Favre-Leuba, while the US founding partner of the mergers and acquisitions firm Duffy & Sweeney, Michael Sweeney, reintroduced the American watch brand Benrus in April. Rosenfield said he believed the recent glut of acquisitions and relaunches of forgotten dial names was sign that luxury buyers want a human connection to their purchases. 'We're so estranged from work with our hands and hand-making and things that are human, and now I think we need this [these brands] more than we ever did,' he said. Initially, Urban Jürgensen watches will be sold direct to consumer. No pre-orders had been taken, according to Rosenfield, who said that in time his strategy allowed for a few 'pop-ups and offices that serve as showrooms' that would be 'places to entertain as much as to sell', a model that has proved successful for Audemars Piguet, which has more than doubled its revenues over the past decade through its network of laid-back AP House concepts. Voutilainen said the ambition was to grow to between 1,000 and 1,200 watches a year in five years, putting it in territory currently dominated by a small number of high-end independents such as F. P. Journe, which was founded in 1999 and is now thought to turn over more than $100 million a year, according to Morgan Stanley estimates. With backing from the Rosenfields and Voutilainen overseeing product development, experts said Urban Jürgensen would shake up the luxury watch industry, currently dominated by Swiss companies. 'This is the best revival of a watch company since A. Lange & Söhne in 1994,' said Wei Koh, founder of the watch media brand Revolution, referring to the German brand now owned by the Richemont Group. 'I hope the Swiss companies are looking over the Atlantic and asking themselves what just happened,' said Kristian Haagen, the Danish founder of Timegeeks and author of multiple books on watchmaking. 'There's something really good and refreshing about it, something extremely un-Swiss. The Rosenfields are extremely wealthy, but they also know their watches.' Co-founders Andy & Alex Rosenfield. (Madison McGaw/ Recent revivals of historic dial names suggest the omens are good. In 2015, the billionaire Scheufele family that owns Chopard introduced Ferdinand Berthoud, named after the 18th century watchmaker. The company has won a number of prestigious industry awards with its small-scale watches, including the Aiguille d'Or at the Grand Prix d'Horlogerie de Genève (GPHG) in 2016, widely viewed as the highest honour in fine watchmaking. It was followed the same year by Czapek & Cie, a name from the 19th century. It too has won a GPHG award and grown a client base with its short-batch collections of hand-finished mechanical watches. The luxury watch industry's current travails appeared not to concern Urban Jürgensen's new owners. While many watch businesses have reported declining sales and volumes over the past 18 months, the pain has been at the lower end of the market. 'At the higher price point, it's not that big a problem,' said Voutilainen. Rosenfield acknowledged that the industry was in better health than it is now when his family acquired the brand in 2021. 'The [relaunch] timing was not planned for this moment,' he said. 'But our view was, when the watches are ready, we'll introduce them. And that is now. There will always be a market for things that are beautiful and unique and made to the highest standard. It just has to be something people want.' He added that his family's investment in Urban Jürgensen was long-term. 'Our hope would be to never sell it,' he said. 'We want to pass it down through generations.'
